New England Journal of Medicine· 2026Q1
Daraxonrasib for Previously Treated RAS -Mutant Non–Small-Cell Lung Cancer
- 2citations
- Q1SCImago
- 2026year
Short summary
Daraxonrasib, an oral tri-complex inhibitor, demonstrated objective response rates over 30% in patients with previously treated advanced RAS-mutant non-small-cell lung cancer (NSCLC).
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Pulmonary and Respiratory Medicine
Pulmonary and Respiratory MedicineMedicine